Dean E McNulty

Title: Dean E. McNulty: Innovator in Pharmaceutical Research

Introduction: Dean E. McNulty, an accomplished inventor based in Philadelphia, PA, has made significant contributions to pharmaceutical research, particularly in the realm of anti-inflammatory drug development. With a total of eight patents to his name, McNulty has demonstrated a commitment to advancing medical science through innovative solutions.

Latest Patents: Among his latest patents is an invention related to "Antibodies produced against cytokine suppressive anti-inflammatory drug binding proteins." This invention focuses on drug binding proteins, the genes encoding them, and methods for screening pharmaceuticals. Specifically, it pertains to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein, along with gene identification and assays valuable for drug evaluation.

Another notable patent is on "Human urotensin II." This patent covers Human Urotensin II polypeptides and polynucleotides and includes methods for producing these polypeptides through recombinant techniques. Furthermore, the patent outlines therapeutic applications and diagnostic assays utilizing Human Urotensin II polypeptides and polynucleotides.

Career Highlights: Dean E. McNulty has held significant positions at renowned organizations, including SmithKline Beecham Corporation, which has played a crucial role in his developmental work in pharmaceuticals.

Collaborations: Throughout his career, McNulty has collaborated with esteemed colleagues such as Peter C. McDonnell and Peter R. Young. These partnerships have contributed to the successful execution of various research projects and patents.

Conclusion: Dean E. McNulty stands out as a pioneer in the field of pharmaceutical innovations. His work not only furthers the understanding of anti-inflammatory processes but also opens new avenues for therapeutic applications, emphasizing the vital role of inventive minds in modern medicine.